Effect of vitamin D supplementation on upper respiratory infections in adults

In healthy adults, is vitamin D supplementation better than placebo for preventing and/or reducing the severity of upper respiratory tract infections?

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000486224

Enrollment

320

Registered

2009-06-18

Start date

2010-02-22

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The main hypothesis of the study is that maintaining an adequate vitamin D level will prevent and/or reduce the severity of upper respiratory infections.

Interventions

Vitamin D3 200,000 IU oral tablet at baseline, then 200,000 IU oral tablet one month later, then 100,000 IU oral tablet monthly for 18 months.

Study design

Allocation

Randomised controlled trial

Primary purpose

Prevention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Age 18 years and over, ability to give informed consent, anticipated residence in Christchurch for the 18-month study period

Exclusion criteria

Use of vitamin D3 supplements, pregnancy, use of immunosuppressants or medications that interfere with vitamin D metabolism, history of hypercalcaemia, nephrolithiasis or sarcoidosis, and current kidney or liver disorders, malignancy and malabsorption.

Outcome results